From: Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Drug (company) | Indication | Pivotal study | Study design | PFS | OS | ORR | Approval time |
---|---|---|---|---|---|---|---|
Sorafenib (Bayer and Onyx) | RCC | NCT00073307 [27] | Phase III, sorafenib vs. placebo | HR = 0.44, p < 0.01 | HR = 0.77, p = 0.02 | 10% vs. 2% | 2005 (FDA) |
HCC | NCT00105443 [28] | Phase III, sorafenib vs. placebo | HR = 0.58, p < 0.001 | HR = 0.69, p < 0.001 | 2% vs. 1% | 2007 (FDA) | |
DTC | NCT00984282 [29] | Phase III, sorafenib vs. placebo | HR = 0.59, p < 0.0001 | HR = 0·80, p = 0·14 | 12.2% vs. 0.5% | 2013 (FDA) | |
Sunitinib (Pfizer) | GIST | NCT00075218 [32] | Phase III, sunitinib vs. placebo | HR = 0.33, p < 0.0001 | HR = 0·49, p = 0·007 | 7% vs. 0% | 2007 (FDA) |
RCC | Phase III, sunitinib vs. INF-a | HR = 0.42, p < 0.001 | HR = 0.82, p = 0.05 | 31% vs. 6% | 2007 (FDA) | ||
pNETs | NCT00428597 [35] | Phase III, sunitinib vs. placebo | HR = 0.42, p < 0.001 | NA | 9.3% vs. 0% | 2011 (FDA) | |
Pazopanib (GlaxoSmith Kline) | RCC | NCT00720941 [37] | Phase III, pazopanib vs. placebo | HR = 0.46, p < 0.0001 | NA | 30% vs. 3% | 2009 (FDA) |
STS | NCT00753688 [42] | Phase III, pazopanib vs. placebo | HR = 0.31, p < 0.0001 | HR = 0.86, p = 0.25 | 9% vs. 0% | 2012 (FDA) | |
Axitinib (Pfizer) | RCC | Phase III, axitinib vs. sorafenib | HR = 0.67, p < 0.0001 | HR = 0.97, p = 0.37 | 19% vs. 9% | 2012 (FDA) | |
Regorafenib (Bayer) | CRC | NCT01103323 [47] | Phase III, regorafenib vs. placebo | HR = 0.49, p < 0.0001 | HR = 0.77. p = 0.005 | 1.0% vs. 0.4% | 2012 (FDA) |
NCT01584830 [48] | Phase III, regorafenib vs. placebo | HR = 0.31, p < 0.0001 | HR = 0.55, p = 0.0002 | 4% vs. 0% | |||
GIST | NCT01271712 [49] | Phase III, regorafenib vs. placebo | HR = 0.27, p < 0.0001 | HR = 0.77, p = 0.199 | 4.5% vs. 1.5% | 2013 (FDA) | |
HCC | NCT01774344 [50] | Phase III, regorafenib vs. placebo | HR = 0.46, p < 0.0001 | HR = 0.63, p < 0.0001 | 11% vs. 4% | 2017 (FDA) | |
Cabozantinib (Exelixis) | MTC | NCT00704730 [53] | Phase III, cabozantinib vs. placebo | HR = 0.28, p < 0.001 | HR = 0.98 | 28% vs. 0% | 2012 (FDA) |
RCC | Phase III, cabozantinib vs. everolimus | HR = 0.58, p < 0.001 | HR = 0.66, p = 0.0003 | 21% vs.5% | 2016 (FDA) | ||
Nintedanib (Boehringer) | IPF | NCT00514683 [60] | Phase II, nintedanib vs. placebo | NA | NA | NA | 2014 (FDA) |
NCT01335464 NCT01335477 [61] | Phase III, nintedanib vs. placebo | ||||||
NSCLC | NCT00805194 [63] | Phase III, docetaxel + nintedanib vs. docetaxel + placebo | HR = 0.79, p = 0.0019 | HR = 0.94, p = 0.27 | 4.4% vs. 3.3% | 2014 (EMA) | |
Lenvatinib (Eisai ) | DTC | NCT01321554 [67] | Phase III, lenvatinib vs. placebo | HR = 0.21, p < 0.001 | HR = 0.73, p = 0.10 | 64.8% vs. 1.5% | 2015 (FDA) |
RCC | NCT01136733 [68] | Phase II, lenvatinib + everolimus vs. lenvatinib vs. everolimus | HR = 0.4, p = 0.0005* | HR = 0.51, p = 0.024* | 43% vs. 27% vs. 6% | 2016 (FDA) | |
HCC | NCT01761266 [69] | Phase III, lenvatinib vs. sorafenib | HR = 0.64, p < 0.0001 | HR = 0.92 | 40.6% vs. 12.4% | 2018 (FDA) | |
Apatinib (Hengrui) | GC | NCT01512745 [73] | Phase III, apatinib vs. placebo | HR = 0.709, p = 0.015 | HR = 0.444, p < 0.001 | 2.8% vs. 0% | 2014 (CFDA) |
Anlotinib (Chia-taiTianqing) | NSCLC | NCT02388919 [76] | Phase III, anlotinib vs. placebo | HR = 0.25, p < 0.001 | HR = 0.68, p = 0.002 | 9.2% vs. 0.7% | 2018 (CFDA) |
Fruquintinib (Hutchison) | CRC | NCT02314819 [80] | Phase III, fruquintinib vs. placebo | HR = 0.26, p < 0.001 | HR = 0.65, p < 0.001 | 4.7% vs. 0% | 2018 (CFDA) |